Key result
Prevalent CVD is linked to ~46% higher odds of rapid 9-year DHEAS decline.
Why the study?
This study aimed to describe cross-sectional and longitudinal associations with dehydroepiandrosterone sulfate (DHEAS) and age-related changes in DHEAS in the oldest old.
Does prevalent cardiovascular disease accelerate longitudinal decline in dehydroepiandrosterone sulfate (DHEAS) levels over 9 years in the oldest old?
Cohort (n=989)
Yes
Does prevalent cardiovascular disease accelerate longitudinal decline in dehydroepiandrosterone sulfate (DHEAS) levels over 9 years in the oldest old?
Answers are grounded in this paper and cite their sources.
Prevalent cardiovascular disease is independently associated with accelerated longitudinal decline in DHEAS levels into the ninth decade of life, suggesting that low DHEAS may reflect underlying vascular disease burden and consequent adrenal endocrine dysfunction.
OBJECTIVES: To describe cross-sectional and longitudinal associations with dehydroepiandrosterone sulfate (DHEAS) and change in DHEAS with age. DESIGN: Longitudinal cohort study. SETTING: Pittsburgh, Pennsylvania. PARTICIPANTS: Cardiovascular Health Study All Stars study participants assessed in 2005/06 (N=989, mean age 85.2, 63.5% women, 16.5% African American). MEASUREMENTS: Health characteristics were assessed in 2005/06 according to DHEAS level, mean DHEAS and DHEAS change across age categories were tested, and linear and logistic regression was used to identify factors present in 1996/97 associated with continuous and categorical DHEAS change. RESULTS: Mean +/- standard deviation DHEAS was 0.555 +/- 0.414 microg/mL in 1996/97 and 0.482 +/- 0.449 microg/mL in 2005/06 for women and 0.845 +/- 0.520 microg/mL in 1996/97 and 0.658 +/- 0.516 microg/mL in 2005/06 for men. In 2005/06, DHEAS was lower in women and subjects with cardiovascular disease (CVD) and chronic pulmonary disease and higher for African Americans and subjects with hypertension and high cholesterol. Mean DHEAS change was greater in men (-0.200 microg/mL) than in women (-0.078 microg/mL) (P<.001). Each 1-year increase in age attenuated the effect of male sex by 0.01 microg/mL (P=.009), abolishing the sex difference in DHEAS change by age 79. Presence of CVD before the study period was associated with greater absolute DHEAS change (beta=-0.04 microg/mL, P=.04) and with the fourth quartile of DHEAS change versus the first to third quartiles (odds ratio=1.46, 95% confidence interval=1.03-2.05). CONCLUSION: DHEAS change continues into very old age, is not homogenous, is affected by sex, and is associated with prevalent CVD. Future studies should investigate factors that might accelerate DHEAS decline.
No takes yet. Share an insight, caveat, or question.
Sanders et al. (2010) conducted a cohort in Dehydroepiandrosterone sulfate (DHEAS) decline and cardiovascular disease in the oldest old (n=989). Prevalent cardiovascular disease (coronary heart disease or cerebrovascular disease) vs. Absence of prevalent cardiovascular disease was evaluated on Fourth quartile of categorical DHEAS decline (vs first to third quartiles) over 9 years (OR 1.46, 95% CI 1.03-2.05). Prevalent cardiovascular disease was associated with greater 9-year DHEAS decline and higher odds of being in the top quartile of DHEAS decline.
Synapse has enriched 10 related papers. Consider them for comparative context: